Tempus AI, Inc.
Nasdaq•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Eric P. Lefkofsky
- Full Time Employees
- 2,300
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 600 West Chicago Avenue Chicago IL United States of America 60654
- IPO Date
- Mar 28, 2012
- CIK
- 0001717115
- Website
- tempus.com
- Similar Companies
- Business
- Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
Company News
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
Tempus Announces Acquisition of Deep 6 AI
Should Investors Buy Tempus AI Stock Right Now?
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
Tempus AI: Buying The Dip After 2025 Guidance Raise
Tempus AI Is a Buy, If You Can Handle the Volatility
Tempus AI Down 13%- Is It Time to Buy?
Nancy Pelosi’s Latest AI Stock Pick Tempus AI Is Up Big Today
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
Tempus AI Earnings: A Promising Business, But There Are Risks
Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript
EARNINGS ALERT: TEM
Tempus Reports Fourth Quarter and Full Year 2024 Results
Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge
3 Biotech/Healthcare Names Under $10 I Am Buying Now
5 stocks Congress is buying in 2025
Tempus to Present at TD Cowen's 45th Annual Health Care Conference